U.S. markets closed

Fusion Pharmaceuticals Inc. (FUSN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.92-0.24 (-2.94%)
At close: 4:00PM EDT

Fusion Pharmaceuticals Inc.

270 Longwood Road South
Hamilton, ON L8P 0A6
289 799 0891

Full Time Employees51

Key Executives

NameTitlePayExercisedYear Born
Dr. John F. ValliantFounder, CEO & Director845.5kN/A1970
Mr. John J. Crowley CPAChief Financial Officer646.43kN/A1974
Dr. Eric BurakChief Scientific Officer600.78kN/A1965
Dr. James J. O'LearyChief Medical Officer537.64kN/A1965
Ms. Lynn WickExec. Director of Fin. & OperationsN/AN/AN/A
Ms. Amanda CraySr. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Maria D. StahlChief Legal OfficerN/AN/A1971
Dr. Marc Schwabish Ph.D.SVP of Bus. Devel. and US OperationsN/AN/AN/A
Dr. Isabelle Dussault Ph.D.Sr. VP of ResearchN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.

Corporate Governance

Fusion Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.